Global University Venturing

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

UCSF spinout Mission Bio has pushed its overall funding to more than $120m following a series C round led by Novo Growth.

Amid the covid-19 pandemic, interest in life sciences is now perhaps at its highest. This is true in corporate venture capital and three of the multimillion-dollar stories we reported in mid-August corroborate this.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Eberhard Karls University of Tübingen's messenger RNA drug developer CureVac priced the offering at the top of its range.

The plant-based food producer boosted its valuation to $4bn and has now raised $1.5bn since being founded by Stanford faculty in 2011.

UChicago has returned for a $35m series B round for Kin Insurance, co-founded by an alumnus of the university’s Booth School of Business.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Uniseed CEO Peter Devine looks back on the journey from Hatchtech's inception to regulatory approval in the US for its head lice treatment.

Vision Medicals secured follow-on funding from Cash Capital in a round that brought the precision diagnostic tool developer's total to $42.8m.

University of Utah's biotech incubator has admitted its first three residents taking aim at cancer, liver fibrosis and eosinophil-related diseases.